Search Results - "Smoot, Rory L."

Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma by Loeuillard, Emilien, Yang, Jingchun, Buckarma, EeeLN, Wang, Juan, Liu, Yuanhang, Conboy, Caitlin, Pavelko, Kevin D, Li, Ying, O'Brien, Daniel, Wang, Chen, Graham, Rondell P, Smoot, Rory L, Dong, Haidong, Ilyas, Sumera

“…Immune checkpoint blockade (ICB) has revolutionized cancer therapeutics. Desmoplastic malignancies, such as cholangiocarcinoma (CCA), have an abundant tumor…”
Get full text

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer by Truty, Mark J., Kendrick, Michael L., Nagorney, David M., Smoot, Rory L., Cleary, Sean P., Graham, Rondell P., Goenka, Ajit H., Hallemeier, Christopher L., Haddock, Michel G., Harmsen, William S., Mahipal, Amit, McWilliams, Robert R., Halfdanarson, Thorvardur R., Grothey, Axel F.

“…MINITotal neoadjuvant therapy, or systemic induction chemotherapy followed by chemoradiation, is an optimal preoperative sequencing strategy for patients with…”
Get full text

YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity by Sugihara, Takaaki, Werneburg, Nathan W, Hernandez, Matthew C, Yang, Lin, Kabashima, Ayano, Hirsova, Petra, Yohanathan, Lavanya, Sosa, Carlos, Truty, Mark J, Vasmatzis, George, Gores, Gregory J, Smoot, Rory L

“…The Hippo pathway effector, Yes-associated protein (YAP), is a transcriptional coactivator implicated in cholangiocarcinoma (CCA) pathogenesis. YAP is known to…”
Get full text

miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma by Razumilava, Nataliya, Bronk, Steve F., Smoot, Rory L., Fingas, Christian D., Werneburg, Nathan W., Roberts, Lewis R., Mott, Justin L.

“…It has been established that microRNA expression and function contribute to phenotypic features of malignant cells, including resistance to apoptosis. Although…”
Get full text

Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database by Shubert, Christopher R., MD, Bergquist, John R., MD, Groeschl, Ryan T., MD, Habermann, Elizabeth B., PhD, Wilson, Patrick M., MPH, Truty, Mark J., MD, Smoot, Rory L., MD, Kendrick, Michael L., MD, Nagorney, David M., MD, Farnell, Michael B., MD

“…Background Outcomes of neoadjuvant systemic therapy versus an upfront operation for clinical, stage III pancreatic adenocarcinoma remain poorly defined. Our…”
Get full text

Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early-Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study by Bergquist, John R., MS, MA, MD, Puig, Carlos A., MD, Shubert, Christopher R., MD, Groeschl, Ryan T., MD, Habermann, Elizabeth B., MPH, PhD, Kendrick, Michael L., MD, FACS, Nagorney, David M., MD, FACS, Smoot, Rory L., MD, Farnell, Michael B., MD, FACS, Truty, Mark J., MS, MD

“…Background Patient triage in anatomically resectable, early-stage pancreatic ductal adenocarcinoma (PDAC) with elevated carbohydrate antigen 19-9 (CA 19-9)…”
Get full text

Platelet‐derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation by Smoot, Rory L., Werneburg, Nathan W., Sugihara, Takaaki, Hernandez, Matthew C., Yang, Lin, Mehner, Christine, Graham, Rondell P., Bronk, Steven F., Truty, Mark J., Gores, Gregory J.

“…The Hippo pathway effector YAP is implicated in the pathogenesis of cholangiocarcinoma (CCA). The Hippo pathway relies on signaling cross talk for its…”
Get full text

Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma by MERTENS, Joachim C, FINGAS, Christian D, GORES, Gregory J, CHRISTENSEN, John D, SMOOT, Rory L, BRONK, Steven F, WERNEBURG, Nathan W, GUSTAFSON, Michael P, DIETZ, Allan B, ROBERTS, Lewis R, SIRICA, Alphonse E

“…Cancer-associated fibroblasts (CAF) are abundant in the stroma of desmoplastic cancers where they promote tumor progression. CAFs are "activated" and as such…”
Get full text

Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients by Gudmundsdottir, Hallbera, Habermann, Elizabeth B., Vierkant, Robert A., Starlinger, Patrick, Thiels, Cornelius A., Warner, Susanne G., Smoot, Rory L., Truty, Mark J., Kendrick, Michael L., Halfdanarson, Thorvardur R., Nagorney, David M., Cleary, Sean P.

“…Background Distant metastases are the strongest predictor of poor prognosis for patients with neuroendocrine tumors (NETs). Cytoreductive hepatectomy (CRH) can…”
Get full text

Clinical Risk Score to Predict Pancreatic Fistula after Pancreatoduodenectomy: Independent External Validation for Open and Laparoscopic Approaches by Shubert, Christopher R., MD, Wagie, Amy E., MHA, Farnell, Michael B., MD, FACS, Nagorney, David M., MD, FACS, Que, Florencia G., MD, FACS, Reid Lombardo, KMarie, MD, Truty, Mark J., MD, Smoot, Rory L., MD, Kendrick, Michael L., MD, FACS

“…Background A clinical risk score for pancreatic fistula (CRS-PF) was recently reported to predict postoperative pancreatic fistula (POPF) after…”
Get full text

The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma by Buckarma, EeeLN H, Werneburg, Nathan W, Conboy, Caitlin B, Kabashima, Ayano, O'Brien, Daniel R, Wang, Chen, Ilyas, Sumera I, Smoot, Rory L

“…The Hippo pathway effector Yes-associated protein (YAP) is localized to the nucleus and transcriptionally active in a number of tumor types, including a…”
Get full text

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration by Ammann, Markus, Santol, Jonas, Pereyra, David, Kalchbrenner, Tamara, Wuerger, Tanja, Laengle, Johannes, Smoot, Rory L., Hulla, Wolfgang, Laengle, Friedrich, Starlinger, Patrick

“…Accumulating evidence suggests that metabolic demands of the regenerating liver are met via lipid metabolism and critical regulators of this process. As such,…”
Get full text

Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy by Maeda, Shimpei, Moore, Alexandra M., Yohanathan, Lavanya, Hata, Tatsuo, Truty, Mark J., Smoot, Rory L., Cleary, Sean P., Nagorney, David M., Grotz, Travis E., Park, Eugene J., Girgis, Mark D., Reber, Howard A., Motoi, Fuyuhiko, Masuda, Toshiro, Unno, Michiaki, Kendrick, Michael L., Donahue, Timothy R.

“…Resection margin status has been recognized as an independent prognostic factor on overall survival in pancreatic cancer patients undergoing surgical…”
Get full text

Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience by Johnson, Benny, Jin, Zhaohui, Truty, Mark J., Smoot, Rory L., Nagorney, David M., Kendrick, Michael L., Kipp, Benjamin R., Grothey, Axel

“…Background BRAF V600E mutations are present in 8%–10% of patients with metastatic colorectal cancer (mCRC) and portend poor prognosis. This study investigated…”
Get full text

FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma by Abdelrahman, Amro M, Goenka, Ajit H, Alva-Ruiz, Roberto, Yonkus, Jennifer A, Leiting, Jennifer L, Graham, Rondell P, Merrell, Kenneth W, Thiels, Cornelius A, Hallemeier, Christopher L, Warner, Susanne G, Haddock, Michael G, Grotz, Travis E, Tran, Nguyen H, Smoot, Rory L, Ma, Wen Wee, Cleary, Sean P, McWilliams, Robert R, Nagorney, David M, Halfdanarson, Thorvardur R, Kendrick, Michael L, Truty, Mark J

“…Neoadjuvant therapy (NAT) is used in borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly…”
Get more information

Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis by Bergquist, John R., Ivanics, Tommy, Storlie, Curtis B., Groeschl, Ryan T., Tee, May C., Habermann, Elizabeth B., Smoot, Rory L., Kendrick, Michael L., Farnell, Michael B., Roberts, Lewis R., Gores, Gregory J., Nagorney, David M., Truty, Mark J.

“…Background Optimal management of patients with intrahepatic cholangiocarcinoma (ICCA) and elevated CA19‐9 remains undefined. We hypothesized CA19‐9 elevation…”
Get full text

YAP-associated chromosomal instability and cholangiocarcinoma in mice by Rizvi, Sumera, Fischbach, Samantha R, Bronk, Steven F, Hirsova, Petra, Krishnan, Anuradha, Dhanasekaran, Renumathy, Smadbeck, James B, Smoot, Rory L, Vasmatzis, George, Gores, Gregory J

“…Deregulated Hippo pathway signaling is associated with aberrant activation of the downstream effector yes-associated protein (YAP), an emerging key oncogenic…”
Get full text

Sorafenib inhibits signal transducer and activator of transcription‐3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2 by Blechacz, Boris R. A., Smoot, Rory L., Bronk, Steven F., Werneburg, Nathan W., Sirica, Alphonse E., Gores, Gregory J.

“…The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is one of the key signaling cascades in cholangiocarcinoma (CCA) cells,…”
Get full text

Molecular and Immunohistochemical Analysis of Mucinous Cystic Neoplasm of the Liver by Van Treeck, Benjamin J, Lotfalla, Mira, Czeczok, Thomas W, Mounajjed, Taofic, Moreira, Roger K, Allende, Daniela S, Reid, Michelle D, Naini, Bita V, Westerhoff, Maria, Adsay, N Volkan, Kerr, Sarah E, Rizvi, Sumera H, Smoot, Rory L, Liu, Yuanhang, Davila, Jaime, Graham, Rondell P

“…Abstract Objectives Mucinous cystic neoplasm of the liver is characterized by neoplastic mucinous and/or biliary epithelium surrounded by ovarian-type stroma…”
Get full text

Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study) by Bergquist, John R., Shah, Harsh N., Habermann, Elizabeth B., Hernandez, Matthew C., Ivanics, Tommy, Kendrick, Michael L., Smoot, Rory L., Nagorney, David M., Borad, Mitesh J., McWilliams, Robert R., Truty, Mark J.

“…Ideal oncologic management of gallbladder carcinoma (GBCA) after complete surgical resection is unclear. We sought to define benefit of post-resection adjuvant…”
Get full text